Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Open Access
- 13 September 2016
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (1) , 246-253
Abstract
We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r + 3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r + 2NUCs) at 96 weeks of follow-up. SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patients. Hepatitis B virus surface antigen-negative subjects with no previous treatment failure/resistance mutations and HIV-1-RNA 3 (95% CI for the difference, −49.3–50.7), grade 3–4 adverse events (70.7% versus 70.2%) and changes in the global deficit score, −0.3 (95% CI, −0.5 to −0.1) for ATV/r + 3TC, versus −0.2 (95% CI, −0.4 to −0.1) for ATV/r + 2NUCs]. The long-term results of switching to ATV/r + 3TC show that this strategy is effective, safe and non-inferior to ATV + 2NUCs in virologically suppressed HIV-infected patients.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of protease inhibitor monotherapyvs. triple therapy: meta‐analysis of data from 2303 patients in 13 randomized trialsHIV Medicine, 2015
- Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialThe Lancet HIV, 2015
- Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trialThe Lancet Infectious Diseases, 2015
- Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trialThe Lancet Infectious Diseases, 2015
- Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot studyJournal of Antimicrobial Chemotherapy, 2015
- Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018Journal of the International AIDS Society, 2014
- The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baselineHIV Medicine, 2012
- 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baselineJournal of Antimicrobial Chemotherapy, 2011
- Predictive Validity of Global Deficit Scores in Detecting Neuropsychological Impairment in HIV InfectionJournal of Clinical and Experimental Neuropsychology, 2004
- Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA StudyAIDS, 2002